Trials / Completed
CompletedNCT05421299
A Study to Assess 7/8 HLA-matched Hematopoietic Stem Cell Transplantation Participants Treated With or Without Abatacept in Combination With a Calcineurin Inhibitor and Methotrexate
Overall Survival in 7/8 HLA-Matched Hematopoietic Stem Cell Transplantation Patients Treated With Abatacept Combined With a Calcineurin Inhibitor and Methotrexate- An Analysis of the Center for International Blood and Marrow Transplant Research (CIBMTR) Database
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 378 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 6 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to estimate overall survival (OS) for participants treated with abatacept versus those not treated with abatacept prior to hematopoietic stem cell transplantation (HSCT). Participants were included if their donors were unrelated and had 1-allele mismatched human leukocyte antigen (HLA) status.
Conditions
Timeline
- Start date
- 2019-09-16
- Primary completion
- 2021-02-15
- Completion
- 2021-02-15
- First posted
- 2022-06-16
- Last updated
- 2022-06-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05421299. Inclusion in this directory is not an endorsement.